Biodel Inc. Announces Commercial Manufacturing Agreement With...
Biodel Inc. today announced another development in its Glucagon Emergency Management development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions .
Biodel Inc. To Present At The 26th Annual Conference
Biodel Inc. management will be presenting an overview of the Company's technologies, development programs, and outlook at the 26th Annual ROTH Conference being held at the Ritz-Carlton Laguna Niguel, CA from March 9-12, 2014.
Biodel Announces Plans to Advance BIOD-531 Based on Positive Clinical Trial Results
Biodel Inc. today announced preliminary results from Study 3-150, a Phase 1 clinical trial comparing Biodel's proprietary insulin formulation, BIOD-531, to the marketed products Humulin R U-500 and Humalog Mix 75/25.
Biodel Reports First Quarter Fiscal Year 2014 Financial Results
Continued progress on the glucagon rescue EZMix GEM program, including completion of dose ranging safety studies in preparation for initiation of GLP toxicology study in the 1st calendar quarter, with projected near term milestones including an IND filing in the 3rd calendar quarter and initiation of pivotal trial in the 4th calendar quarter of ... (more)
Biodel Inc. To Report First Quarter Fiscal Year 2014 Financial Results On February 6, 2014
Biodel Inc. will issue its first quarter fiscal year 2014 financial results on February 6, 2014.